With over 15 years' experience in the patent profession, David deals with a wide range of life science subject matter, including molecular biology, genetics, transgenic animals, immunology, vaccines, recombinant DNA methodology and transgenic crop plants.
David has experience of filing and prosecuting patent applications in all major territories, particularly in Europe, the USA, Japan, Korea and Australia, but also in further-flung jurisdictions via experience of prosecution of some large patent families covering needleless injection, vaccine technology and two biopharmaceuticals that are now marketed drugs. He also acts to coordinate foreign law information within JA Kemp on many countries.
He has also acted in oppositions and appeals before the European Patent Office, representing both patent proprietors and opponents. David's background is in genetics and his PhD and postdoctoral work related to gene targeting in mice so he has particular expertise regarding transgenic animals as models for human disease and research tools. He has recently concluded a successful Opposition/Appeal process on transgenic mice as antibody production platforms and is involved in a number of other prosecution and opposition matters in this area.
David's clients include large corporations, small and mid-size biotechnology companies in the UK, Japan and the USA David joined J A Kemp in 1999 and became a partner in 2009.
Newcastle University, Honours Degree in Genetics; University College London, PhD in Biochemistry followed by post-doctoral research in Immunology
European Patent Attorney, UK Chartered Patent Attorney
Fellow of the Chartered Institute of Patent Attorneys (CIPA), Member of the Institute of Professional Representatives before the European Patent Office (EPI)